Summary & Overview
AICD Generator Procedures: Inpatient Reimbursement Overview
DRG 245 encompasses inpatient procedures for automatic implantable cardioverter-defibrillator generator implantation, replacement, or revision and is used to classify resource use for device-related hospital admissions. It matters for inpatient reimbursement because it bundles procedure-related costs and influences Medicare payment for device, operating room, and postoperative care.
DRG 245 Overview
DRG 245 covers inpatient admissions for implantation, replacement, or revision of automatic implantable cardioverter-defibrillator generator devices. This Diagnosis-Related Group captures procedures performed by cardiology and cardiothoracic teams and is significant because it groups resource use related to device costs, operating room time, and postprocedural monitoring. For Medicare payment, DRG 245 determines bundled hospital reimbursement for the episode of care, influencing inpatient payment rates and billing classification. Accurate coding of the procedure and any associated diagnoses affects case assignment and reimbursement.
Clinical Trials
- Acute perioperative device safety and implantation technique studies: randomized or observational studies assessing immediate and early complications of implantable cardioverter-defibrillator (AICD) generator procedures, such as pocket hematoma, lead dislodgement, infection, and peri‑procedural arrhythmias. These studies enroll patients undergoing generator replacement or initial generator implantation, often stratified by anticoagulation status, presence of cardiac resynchronization therapy leads, or prior device infection. Results inform procedural protocols, perioperative management, and short‑term resource utilization, which are directly relevant to inpatient clinicians and payers focused on reducing complications, readmissions, and costly reinterventions.
- Comparative effectiveness research on device programming and generator selection in high‑risk subgroups: pragmatic trials or cohort studies comparing different generator models, battery longevity strategies, or programming algorithms (e.g., shock thresholds, detection intervals) in populations such as elderly patients, those with heart failure, or patients with prior shocks. These studies examine outcomes like inappropriate shocks, device longevity, quality of life, and downstream healthcare utilization over months to years after implantation. Findings guide clinicians and payers in selecting devices and programming strategies that balance upfront device cost against long‑term outcomes, replacement frequency, and total cost of care for patients classified under this DRG.
- Post‑discharge outcomes and care‑coordination interventions to reduce readmissions and infections: pragmatic studies testing discharge protocols, remote monitoring programs, antibiotic stewardship around generator replacement, or structured wound care follow‑up in patients after AICD generator procedures. These trials typically focus on transition‑of‑care populations with comorbidities such as diabetes, renal disease, or anticoagulation therapy that increase post‑procedural risk. Evidence from these studies helps hospitals and payers design care pathways that lower readmission rates, reduce post‑operative infections, and optimize resource allocation for this inpatient population.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.